• PrSandoz® Semaglutide, a generic version of PrOzempic®, approved for the treatment of adult patients with type 2 diabetes
• This lower-cost alternative supports improved affordability and access to type 2 diabetes treatments across Canada
• An important milestone in further strengthening Sandoz Canada's established diabetes portfolio

SAINT-HUBERT, QC, Sept. 18, 2026 /CNW/ -- Sandoz Canada Inc. today announces that Health Canada has granted authorization to market PrSandoz® Semaglutide, a generic version of Novo Nordisk's PrOzempic®, bringing Canadian patients one step closer to greater access. PrSandoz® Semaglutide has been approved for the once-weekly treatment of adult patients with type 2 diabetes to improve glycemic control, in combination with lifestyle changes and other antidiabetic agents1.

The generic version of semaglutide is a complex synthetic product that is pharmaceutically equivalent to the brand name biologic drug. The Notice of Compliance was issued for three doses delivered subcutaneously via two pen presentations: a pen delivering 0.25 mg or 0.5 mg doses (containing 2 mg of semaglutide [1.34 mg/mL]), and a pen delivering 1 mg doses (containing 4 mg of semaglutide [1.34 mg/mL]).

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.